Ethnically diverse ipsc-cardiomyocyte panel for pharmacogenomics and drug safety testing
Ended Project Grant Awarded Last action
- Award ID
- R44HL170756
- Recipient
-
Greenstone Biosciences, Inc. UEI ETE2HHEYPAV7
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,741,939
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Cardiotoxicity is a leading cause of early and late-stage drug attrition during pharmaceutical development. The FDA now mandates that all new drugs be tested for cardiotoxicity before entering clinical trials. However, there needs to be a safety screening platform that can swiftly detect cardiotoxicity cost-effectively, even before investing too much time and resource in a drug development pipeline. This is further complicated by genomic susceptibility in the population and how they respond to drugs. A tool that can incorporate the influences of SEX, ethnicity, and genetic background can provide accurate data on the safety and efficacy of drugs and stratify patient populations to identify responders versus non-responders. In this sbir grant, we propose to mitigate this issue by providing pharmacogenomics and precision medicine platforms using human induced pluripotent stem cell-derived cardiomyocytes (IPSC-CMS). Our product is a kit comprising 100 unique and ethnically diverse IPSC lines with equal SEX representation. We aim to develop and validate this tool as a surrogate in vitro model for predicting drug toxicity in patient groups at high risk for drug-induced arrhythmia. The study will use the "cell village" platform to CO-culture 10 different patient-specific IPSC lines simultaneously. We will scale this up by multiplexing data from 100 different donors to identify cell-type-specific expression quantitative trait loci (EQTL) using single-cell RNA sequencing (SCRNA-SEQ) and whole genome sequencing (WGS). As a proof-of-principle, we will also assess inter-individual and intra-individual variability in responses to the chemotherapeutic agent doxorubicin. Finally, greenstone biosciences, INC is a biotechnology company located at the stanford research park. Greenstone uses latest advances in clinical genomics, computational biology, and patient-specific ipscs to understand pharmacogenomics and to accelerate drug discovery.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $1,447,258 | |
| Original award | $1,294,681 |
Quick answers
Who received award R44HL170756?
R44HL170756 was awarded to Greenstone Biosciences, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 5, 2023.
How much is award R44HL170756 worth?
$2,741,939 has been obligated on R44HL170756.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award